C12
BillableMalignant neoplasm of pyriform sinus
Last updated: FY2026 ICD-10-CM (Oct 1, 2025 – Sep 30, 2026) | CMS-HCC V28 (100% phase-in, PY2026)
Is C12 an HCC code?
Yes. C12 maps to Breast, Prostate, Colorectal and Other Cancers and Tumors under the CMS-HCC V28 risk adjustment model (and Colorectal, Bladder, and Other Cancers under V24).
HCC Category Mapping
RAF weights shown are the community, non-dual, aged base weights from the CMS risk adjustment model file. Actual per-patient RAF contribution depends on member segment, interactions, and the model year used by the payer. V28 is the CMS-HCC model phased in over payment years 2024–2026; V24 remains in use during the transition and for historical data.
MEAT Criteria for C12
For C12 to count as a valid HCC diagnosis in a given encounter, the provider's documentation must show MEAT: Monitor, Evaluate, Assess, or Treat. A diagnosis from a prior year does not carry forward automatically — it has to be re-documented and supported each calendar year.
- MMonitor: signs, symptoms, disease progression, or lab trending documented in the note
- EEvaluate: test results, medication response, or physical findings reviewed by the provider
- AAssess: explicit mention in the assessment or plan with acknowledgment of status
- TTreat: medication, referral, procedure, therapy, or counseling tied to the diagnosis
Only one of M/E/A/T is required to support the code, but the documentation must be specific enough to show that the provider actually addressed C12 during that encounter — not just copy-forwarded from a problem list.
What This Code Means
C12 is the ICD-10-CM diagnosis code for malignant neoplasm of pyriform sinus. Cancer that develops in the pyriform sinus, a small pouch-shaped area on either side of the lower throat. C12 sits in the ICD-10-CM chapter for neoplasms (c00-d49), within the section covering malignant neoplasms of lip, oral cavity and pharynx (c00-c14).
Under the CMS-HCC V28 risk adjustment model, C12 maps to Breast, Prostate, Colorectal and Other Cancers and Tumors (HCC 21) with a community, non-dual, aged base RAF weight of 0.545. Under the older CMS-HCC V24 model, C12 maps to Colorectal, Bladder, and Other Cancers (HCC 11) with a community, non-dual, aged base RAF weight of 0.306. V28 is the CMS-HCC risk adjustment model that reached 100% phase-in for payment year 2026, replacing V24 which was used during the PY2024–PY2025 transition.
The pyriform sinus is part of the hypopharynx; verify this code is not confused with other hypopharyngeal sites. Because C12 maps to a payment HCC, the provider's documentation must satisfy MEAT criteria (Monitor, Evaluate, Assess, or Treat) for the encounter to count toward the patient's Medicare Advantage risk adjustment score. When documentation is ambiguous, coders should issue a provider query rather than assume the highest-specificity variant.
HCC Buddy maintains structured V28 and V24 mapping, RAF weights, and MEAT documentation criteria for C12 sourced directly from the CMS-HCC risk adjustment model files and the CMS ICD-10-CM code set.
Coding Tips
- •The pyriform sinus is part of the hypopharynx; verify this code is not confused with other hypopharyngeal sites
- •Pyriform sinus cancers often present late due to the deep location and may have poor prognosis
Clinical Significance
Malignant neoplasm of the pyriform sinus is the most common hypopharyngeal cancer, accounting for approximately 65-85% of all hypopharyngeal malignancies. It carries a poor prognosis because tumors in this deep, hidden location often present at advanced stages with regional or distant metastases already present.
Documentation Requirements
- ✓Pathology-confirmed malignancy (squamous cell carcinoma in vast majority)
- ✓Laterality (right or left pyriform sinus)
- ✓TNM staging with assessment of laryngeal invasion and cartilage involvement
- ✓Assessment of vocal cord mobility as staging criterion
- ✓Nutritional status evaluation (dysphagia and weight loss are common)